Application of plasma protein combination in pancreatic cancer screening

By detecting GCLC, ALAD, HAGH, and SORD proteins in the plasma of pancreatic cancer patients using mass spectrometry and combining this with a binary logistic regression model, the low sensitivity and false negatives of existing pancreatic cancer screening technologies have been resolved, achieving efficient early screening for pancreatic cancer and making it suitable for large-scale population screening.

CN122109536AActive Publication Date: 2026-05-29ACADEMY OF MILITARY MEDICAL SCIENCES +2
9 Cites 0 Cited by

Patent Information

Application Number
CN202610575121.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-28
Publication Date
2026-05-29
Estimated Expiration
2046-04-28

AI Technical Summary

Technical Problem

Existing pancreatic cancer screening methods, such as imaging examinations, have limited sensitivity and are costly, while plasma biomarkers, such as CA19-9, have problems such as low sensitivity and false negatives, making it difficult to achieve early screening of large populations.

Method used

Mass spectrometry was used to detect four proteins—GCLC, ALAD, HAGH, and SORD—in the plasma of pancreatic cancer patients. Combined with a binary logistic regression model, pancreatic cancer was identified by quantitative protein abundance, and the formula P = 1/(1+e-(-75.635+2.189×GCLC+0.378×ALAD+0.317×HAGH+0.681×SORD) was used for discrimination.

Benefits of technology

It significantly improves the sensitivity and specificity of pancreatic cancer screening, with an overall accuracy of 0.93 and an AUC of 0.96 in the independent validation set. It is suitable for non-invasive, scalable population screening and has good stability and reproducibility.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of proteomics and clinical disease screening, and relates to application of a plasma protein combination in pancreatic cancer screening. Based on a mass spectrum quantitative proteomics technology, a marker combination composed of four plasma proteins of GCLC, ALAD, HAGH and SORD is screened and determined, the relative abundance of the marker combination is comprehensively analyzed through a binary Logistic regression model, and the marker combination is used for distinguishing pancreatic cancer patients from healthy people. Experimental results show that the protein combination shows relatively high sensitivity, specificity and area under curve (AUC) in a screening set and an independent verification set, and has good stability and repeatability. The method takes plasma as a detection sample, has the advantages of being noninvasive, feasible to operate and suitable for crowd screening, and can provide a new technical means for early screening of pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art